1. Raghu G., Remy-Jardin M., Myers J.L. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 2018; 198 (5): e44-e68. https://doi.org/10.1164/rccm.201807-1255ST.
2. Skandamis A., Kani C., Markantonis S.L., Souliotis K. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis. J. Drug Assess. 2019; 8 (1): 55-61. https://doi.org/10.1080/21556660.2019.1597726.
3. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмонология. 2016; 26 (4): 399-419. https://doi.org/10.18093/0869-0189-2016-26-4-399-419.
4. Авдеев С.Н., Чикина С.Ю., Нагаткина О.В. Идиопатический легочный фиброз: новые международные клинические рекомендации. Пульмонология. 2019; 29 (5): 525-552. https://doi.org/10.18093/0869-0189-2019-29-5-525-552.
5. Lynch D.A., Sverzellati N., Travis W.D. et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir. Med. 2018; 6 (2): 138-153. https://doi.org/10.1016/S2213-2600(17)30433-2.
6. Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015; 13: 237. https://doi.org/10.1186/s12916-015-0495-0.
7. Costabel U., Crestani B., Wells A.U., eds. Idiopathic Pulmonary Fibrosis. ERS Monograph; 2016. https://doi.org/10.1183/2312508X.erm7116.
8. Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46 (1): 186-196. https://doi.org/10.1183/09031936.00217614.
9. Fernández-Fabrellas E., Molina-Molina M., Soriano J.B. et al. Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. Respir. Res. 2019; 20: 127. https://doi.org/10.1186/s12931-019-1084-0.
10. Jo H.E., Glaspole I., Grainge C. et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur. Respir. J. 2017; 49 (2). pii: 1601592. https://doi.org/10.1183/13993003.01592-2016.
11. Wuyts W.A., Dahlqvist C., Slabbynck H. et al. Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. BMJ Open Respir. Res. 2018; 5: e000331. https://doi.org/10.1136/bmjresp-2018-000331.
12. Snyder L., Neely M.L., Hellkamp A.S. et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir. Res. 2019; 20: 105. https://doi.org/10.1186/s12931-019-1043-9.
13. Kaunisto J., Salomaa E.R., Hodgson U. et al. Demo - graphics and survival of patients with idiopathic pulmonary fibrosis in the Finnish IPF registry. ERJ Open Res. 2019; 5 (3). pii: 00170-2018. https://doi.org/10.1183/23120541.00170-2018.
14. Doubková M., Uher M., Bartoš V. et al. [Idiopathic pulmonary fibrosis prognostic factors - analysis of the Czech registry]. Cas. Lek. Cesk. 2016; 155 (4): 22-28 (in Czech).
15. Doubková M., Švancara J., Svoboda M. et al. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin. Respir. J. 2018; 12 (4): 1526-1535. https://doi.org/10.1111/crj.12700.
16. Flaherty K.R., Kolb M., Vancheri C. et al. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2018; 52 (2). pii: 1702593. https://doi.org/10.1183/13993003.02593-2017.
17. Distler O., Highland K.B., Gahlemann M. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 2019; 380 (26): 2518-2528. https://doi.org/10.1056/NEJMoa1903076.
18. Flaherty K.R., Brown K.K., Well A.U. et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir. Res. 2017; 4 (1): e000212. https://doi.org/10.1136/bmjresp-2017-000212.
19. Khanna D., Albera C. Fischer A. et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J. Rheumatol. 2016; 43 (9): 1672- 1679. https://doi.org/10.3899/jrheum.151322.
20. Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183 (6): 788-824. https://doi.org/10.1164/rccm.2009-040GL.
21. Yu X., Li X., Wang L. et al. Pulmonary rehabilitation for exercise tolerance and quality of life in IPF patients: a systematic review and meta-analysis. Biomed. Res. Int. 2019; ID: 8498603. https://doi.org/10.1155/2019/8498603.
22. Florian J., Watte G., Teixeira P.J.Z. et al. Pulmonary rehabilitation improves survival in patients with idiopathic pulmonary fibrosis undergoing lung transplantation. Sci. Rep. 2019; 9: 9347. https://doi.org/10.1038/s41598-019-45828-2.